[1]Siegel RL，Miller KD，Jemal A．Cancer statistics，2016［J］．CA Cancer J Clin，2016，66：7-30．
[2]Haas GP，Barry-Delongchamps N，Jones RF，et al.Needle biopsies on autopsy prostates：Sensitivity of cancer detection based on true prevalence［J］.Natl Cancer Inst，2007，99：1484-1489.
[3]Briganti A，Suardi N，Gallina A，et al.Predicting the risk of bone metastasis in prostate cancer［J］.Cancer Treat Rev，2014，40(1)：3-11.
[4]Heidenreich A，Aus G，Bolla M，et al．Eau guidelines on prostate cancer［J］．Eur Urol，2008，53(1)：68－80．
[5]Qiu JD，Li R，Wang JD，et al.Advances in antitumor effects of zoledronic acid in breast cancer［J］.Academic Journal of Chinese Pla Medical School，2015，36(6)：634-636，643.［邱镜丹，李荣，王建东，等．唑来膦酸在乳腺癌中抗肿瘤作用的研究进展［J］．解放军医学院学报，2015，36(6)：634-636，643．］
[6]Wang Y，Gao X，Yang Q，et al.Advances in the mechanism of bone metastasis in prostate cancer［J］.Chinese Journal of Urology，2015，36(9)：715-717.［王野，高旭，杨庆，等．前列腺癌骨转移发生机制的研究进展［J］．中华泌尿外科杂志，2015，36(9)：715-717.］
[7]Chen Zhibin，Fu Chengzhong，Cheng Zhili，et al.Clinical analysis of bone metastasis related symptom as the first manifestation in prostate cancer［J］.Modern Oncology，2016，24(10)：1595-1597.［陈智彬，傅承忠，程支利，等．以骨转移癌为首发表现的前列腺癌诊治分析［J］． 现代肿瘤医学，2016，24(10)：1595-1597.］
[8]Jambor I，Kuisma A，Ramadan S，et al．Prospective evaluation of planar bone scintigraphy，SPECT，SPECT／CT，18F-NaF PET／CT and whole body 1.5 T MRI，including DWI，for the detection of bone metastases in high risk breast and prostate cancer patients：SKELETA clinical trial［J］.Acta Oncol，2016，55(1)：1-9.
[9]Garcia JR，Riera E，Valls E，et al.Metabolic and osteogenic pattern of prostate cancer bone metastases［J］.Rev Esp Med Nucl Imagen Mol，2013，32(1)：33-36.
[10]Park JC，Eisenberger MA.Advances in the treatment metastatic prostate cancer［J］.Mayo Clin Proc，2015，90（12）：1719-1733.
[11]Chien TM，Lu YM，Geng JH，et al．Predictors of positive bone metastasis in newly diagnosed prostate cancer patients［J］．Asian Pac J Cancer Prev，2016，17：1187-1191．
[12]Liu Y，Xu Y，Liu RL，et al.Diagnostic value of combining detection of PSA and PSAD in patients with prostate cancer bone metastasis［J］.Shandong Medical Journal，2015，5：1-3．［刘妍，徐勇，刘冉录，等．血清PSA、PSAD检测在前列腺癌骨转移诊断中的价值［J］．山东医药，2015，5：1-3．］
[13]Newling DW，Denis L，Vermeylen K.Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer.Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853［J］.Cancer，1993，72(12 suppl)：3793-3798.
[14]Liu L，Liang DJ，Liu HH，et al.Histopathological features of bone metastases from prostatic carcinoma after castration［J］.Chin J Urol，2003，24(5)：321-323.
[15]Lin JM，Liu JM，Zhou Y，et al.Risk factors and characteristics of prostate cancer bone metastases［J］.Med J Chin PLA，2017，42（8）：707-710.［林军明，刘家明，周扬，等.前列腺癌骨转移的特点及其相关危险因素分析［J］.解放军医学杂志，2017，42（8）：707-710.］
[16]Marcel S，Aeilko Z，Jaap Z，et al.The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram［J］.Eur J Nucl Med，1997，24：1215-1219.
[17]James L，Andre J，Roben R，et al.NCCN clinical practice guidelines in oncology：Prostate cancer［J］.Natl Compr Canc Net，2011，8(2)：162-200.
[18]Birtle AJ，Freeman A，Masters JR，et al.Clinical features of patients who present with metastatic prostate carcinoma and serum prostate specific antigen（PSA) levels<10 μg/L：The "PSA negative" patients［J］.Cancer，2003，98（11)：2362-2367.